Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 967-971

  Neustadt, Bernard R ^a   Liu, Hong ^a   Hao, Jinsong ^a   Greenlee, William J ^a   Stamford, Andrew W ^a   Foster, Carolyn ^a   Arik, Leyla ^a   Lachowicz, Jean ^a   Zhang, Hongtao ^a   Bertorelli, Rosalia ^b   Fredduzzi, Silva ^b   Varty, Geoffrey ^a   Cohen Williams, Mary ^a   Ng, Kwokei ^a  

^a Departments of Chemical Research   (United States)

^b Schering Plough Research Institute   (Italy)

Author keywords

1,2,4 Triazolo 1,5 c pyrimidine; Adenosine A2a; Parkinson's disease

Indexed keywords

1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; ADENOSINE A2A RECEPTOR ANTAGONIST; HALOPERIDOL; SCH 420814; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PARKINSON DISEASE; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CATALEPSY; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HALOPERIDOL; MODELS, CHEMICAL; PARKINSON DISEASE; PYRIMIDINES; RATS; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

HUMAN ECHOVIRUS 1; RATTUS;

EID: 58549113972     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.075     Document Type: Article

References (27)

1. Jacobson K.A., van Galen P.J.M., and Williams M. J. Med. Chem. 35 (1992) 4007
2. Muller C.E. Drugs Future 25 (2000) 1043
3. Bara-Himenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Neurology 61 (2003) 293
4. Hauser R.A., Hubble J.P., and Truong D.D. Neurology 251 (2003) 297
5. Neustadt B.R., Hao J., Lindo N., Greenlee W.J., Stamford A.W., Tulshian D., Ongini E., Hunter J., Monopoli A., Bertorelli A., Foster C., Arik L., Lachowicz J., Ng K., and Feng K.-I. Bioorg. Med. Chem. Lett. 17 (2007) 1376
6. 2A antagonist. Slee D.H., Zhang X., Moorjani M., Lin E., Lanier M.C., Chen Y., Rueter J.K., Lechner S.M., Markison S., Malany S., Joswig T., Santos M., Gross R.S., Williams J.P., Castro-Palomino J.C., Crespo M.I., Prat M., Gual S., Diaz J.-L., Wen J., O'Brien Z., and Saunders J. J. Med. Chem. 51 (2008) 400
7. Moorjani M., Zhang X., Chen Y., Lin E., Rueter J.K., Gross R.S., Lanier M.C., Tellew J.E., Williams J.P., Lechner S.M., Malany S., Santos M., Ekhlassi P., Castro-Palomino J.C., Crespo M.I., Prat M., Gual S., Diaz J.-L., Saunders J., and Slee D.H. Bioorg. Med. Chem. Lett. 18 (2008) 1269
8. Zhang X., Rueter J.K., Chen Y., Moorjani M., Lanier M.C., Lin E., Gross R.S., Tellew J.E., Williams J.P., Lechner S.M., Markison S., Joswig T., Malany S., Santos M., Castro-Palomino J.C., Crespo M.I., Prat M., Gual S., Diaz J.-L., Saunders J., and Slee D.H. Bioorg. Med. Chem. Lett. 18 (2008) 1778
9. Slee D.H., Chen Y., Zhang X., Moorjani M., Lanier M.C., Lin E., Rueter J.K., Williams J.P., Lechner S.M., Markison S., Malany S., Santos M., Gross R.S., Jalali K., Sai Y., Zuo Z., Yang C., Castro-Palomino J.C., Crespo M.I., Prat M., Gual S., Diaz J.-L., and Saunders J. J. Med. Chem. 51 (2008) 1719
10. Slee D.H., Moorjani M., Zhang X., Lin E., Lanier M.C., Chen Y., Rueter J.K., Lechner S.M., Markison S., Malany S., Joswig T., Santos M., Gross R.S., Williams J.P., Castro-Palomino J.C., Crespo M.I., Prat M., Gual S., Diaz J.-L., Jalali K., Sai Y., Zuo Z., Yang C., Wen J., O'Brien Z., Petroski R., and Saunders J. J. Med. Chem. 51 (2008) 1730
11. Gillespie R.J., Adams D.R., Bebbington D., Benwell K., Cliffe I.A., Dawson C.E., Dourish C.T., Fletcher A., Gaur S., Giles P.R., Jordan A.M., Knight A.R., Knutsen L.J.S., Lawrence A., Lerpiniere J., Misra A., Porter R.H.P., Pratt R.M., Shepherd R., Upton R., Ward S.E., Weiss S.M., and Williamson D.S. Bioorg. Med. Chem. Lett. 18 (2008) 2916
12. Gillespie R.J., Cliffe I.A., Dawson C.E., Dourish C.T., Gaur S., Giles P.R., Jordan A.M., Knight A.R., Lawrence A., Lerpiniere J., Misra A., Pratt R.M., Todd R.S., Upton R., Weiss S.M., and Williamson D.S. Bioorg. Med. Chem. Lett. 18 (2008) 2920
13. Gillespie R.J., Cliffe I.A., Dawson C.E., Dourish C.T., Gaur S., Jordan A.M., Knight A.R., Lerpiniere J., Misra A., Pratt R.M., Roffey J., Stratton G.C., Upton R., Weiss S.M., and Williamson D.S. Bioorg. Med. Chem. Lett. 18 (2008) 2924
14. Shah U., Boyle C.D., Chackalamannil S., Neustadt B.R., Lindo N., Greenlee W.J., Foster C., Arik L., Zhai Y., Ng K., Monopoli A., and Lachowicz J.E. Bioorg. Med. Chem. Lett. 18 (2008) 4199
15. Shah U., Lankin C.M., Boyle C.D., Chackalamannil S., Greenlee W.J., Neustadt B.R., Cohen-Williams M., Higgins G.A., Ng K., Varty G.B., Zhang H., and Lachowicz J.E. Bioorg. Med. Chem. Lett. 18 (2008) 4204
16. Sch 420814 has recently received the designation of preladanant.
17. Matasi J.J., Caldwell J.P., Zhang H., Fawzi A., Cohen-Williams M.E., Varty G.B., and Tulshian D.B.I. Bioorg. Med. Chem. Lett. 15 (2005) 3670
18. Matasi J.J., Caldwell J.P., Zhang H., Fawzi A., Higgins G.A., Cohen-Williams M.E., Varty G.B., and Tulshian D.B.I. Bioorg. Med. Chem. Lett. 15 (2005) 3675
19. This work was presented in part at the symposium 'Targeting Adenosine A2A Receptors in Parkinson's Disease and Other CNS Disorders', Boston (May 2006).
20. Peng H., Kumaravel G., Yao G., Sha L., Wang J., VanVlijmen H., Bohnert T., Huang C., Vu C.B., Ensinger C.L., Chang H., Engber T.M., Whalley E.T., and Petter R.C. J. Med. Chem. 47 (2004) 6218
21. Vu C.B., Pan D., Peng B., Sha l., Kumaravel G., Jin X., Phadke D., Engber T., Huang C., Reilly J., Tam S., and Petter R.C. Bioorg. Med. Chem. Lett. 14 (2004) 4831
22. Vu C.B., Shields P., Peng B., Kumaravel G., Gin X., Phadke D., Wang J., Engber T., Ayyub E., and Petter R.C. Bioorg. Med. Chem. Lett. 14 (2004) 4835 Compounds 16 and 18 of that report correspond to 16e and 16g of this report. Utilization of our intermediate 19 is described
23. This synthetic methodology differs significantly from that reported in Refs. 8 and 9.
24. i.
25. b = 0.5 nM, the similarity to the series of antagonist 1a, and the anti-cataleptic activity shown by these compounds.
26. Plasma levels were determined in the rat over a 6h period employing cassette dosing as described in. Korfmacher W.A., Cox K.A., Ng K.J., Veals J., Hsieh Y., Wainhaus S., Broske L., Prelusky D., Nomeir A., and White R.E. Rapid Commun. Mass Spectrom. 15 (2001) 335
27. Assay methodology described in. Ongini E., Dionosotti S., Gessi S., Irenius E., and Fredholm B.B. Naunyn Schmiederbergs Arch. Pharmacol. 359 (1999) 7